Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$6.56
-6.0%
$6.66
$4.09
$17.24
$149.21M0.84282,861 shs189,465 shs
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$1.36
$1.23
$0.92
$22.50
$81.29M0.48379,391 shs195,929 shs
NextCure, Inc. stock logo
NXTC
NextCure
$0.40
-15.6%
$0.47
$0.22
$1.82
$13.13M1.06129,840 shs395,101 shs
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
$18.03
$18.03
$5.31
$31.73
$1.42B2.323.17 million shsN/A
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
$17.59
$17.67
$9.93
$32.94
$818.60M1.454,965 shsN/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-2.10%-11.53%-7.92%+48.83%-52.19%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
+0.74%+0.37%+0.74%+13.33%-80.60%
NextCure, Inc. stock logo
NXTC
NextCure
+4.04%+7.14%-14.93%+60.89%-70.37%
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
3.682 of 5 stars
3.42.00.04.70.02.50.0
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
4.4878 of 5 stars
3.04.00.04.62.33.30.6
NextCure, Inc. stock logo
NXTC
NextCure
4.5454 of 5 stars
3.33.00.04.33.31.71.3
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.80
Moderate Buy$18.00174.39% Upside
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1.90
Reduce$5.50304.41% Upside
NextCure, Inc. stock logo
NXTC
NextCure
2.67
Moderate Buy$3.50786.08% Upside
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
0.00
N/AN/AN/A
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PTLA, IGMS, NXTC, ENTA, and ZEAL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
NextCure, Inc. stock logo
NXTC
NextCure
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
7/1/2025
NextCure, Inc. stock logo
NXTC
NextCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
6/3/2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$67.64M2.07N/AN/A$6.08 per share1.08
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$2.68M30.34N/AN/A$0.82 per share1.66
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/A$2.34 per shareN/A
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
$116.64M12.13N/AN/A$1.67 per share10.80
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
$46.54M17.59N/AN/A$3.38 per share5.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$116.04M-$4.54N/AN/AN/A-149.57%-79.83%-26.65%8/4/2025 (Estimated)
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$195.79M-$3.270.00N/AN/A-7,417.79%-317.97%-71.43%8/13/2025 (Estimated)
NextCure, Inc. stock logo
NXTC
NextCure
-$55.65M-$1.760.00N/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
-$290.66M-$4.06N/AN/AN/A-232.73%-267.86%-54.66%N/A
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
-$161.99M-$4.09N/AN/AN/A-565.44%-111.04%-56.54%N/A

Latest PTLA, IGMS, NXTC, ENTA, and ZEAL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
NextCure, Inc. stock logo
NXTC
NextCure
-$0.39N/AN/AN/AN/AN/A
8/4/2025Q3 2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.10N/AN/AN/A$16.21 millionN/A
5/13/2025Q1 2025
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million
5/12/2025Q2 2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million
5/1/2025Q1 2025
NextCure, Inc. stock logo
NXTC
NextCure
-$0.40-$0.39+$0.01-$0.39N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/AN/AN/AN/AN/A
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/AN/A
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
N/AN/AN/AN/AN/A
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
5.29
5.29
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/A
5.71
5.71
NextCure, Inc. stock logo
NXTC
NextCure
N/A
10.26
10.26
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
4.77
4.87
4.82
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
0.93
4.79
4.78

Institutional Ownership

CompanyInstitutional Ownership
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
94.99%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
42.79%
NextCure, Inc. stock logo
NXTC
NextCure
42.65%
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
98.68%
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
1.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
16021.38 million18.41 millionOptionable
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
19059.78 million25.70 millionOptionable
NextCure, Inc. stock logo
NXTC
NextCure
9028.05 million23.03 millionOptionable
Portola Pharmaceuticals, Inc. stock logo
PTLA
Portola Pharmaceuticals
32478.48 millionN/AOptionable
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
35546.54 million45.51 millionNot Optionable

Recent News About These Companies

Zealand Pharma Appoints Chief Development Officer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$6.56 -0.42 (-6.02%)
Closing price 04:00 PM Eastern
Extended Trading
$6.56 0.00 (-0.08%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

IGM Biosciences stock logo

IGM Biosciences NASDAQ:IGMS

$1.36 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.35 -0.01 (-1.03%)
As of 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

NextCure stock logo

NextCure NASDAQ:NXTC

$0.40 -0.07 (-15.63%)
Closing price 03:59 PM Eastern
Extended Trading
$0.43 +0.04 (+9.62%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Portola Pharmaceuticals stock logo

Portola Pharmaceuticals NASDAQ:PTLA

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Zealand Pharma A/S stock logo

Zealand Pharma A/S NASDAQ:ZEAL

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.